Zensun’s Neucardin HF drug is fast-tracked by the FDA. Neucardin is a recombinant...
- GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
- Trials data suggests Cosentyx from Novartis will change psoriasis market
- Eligibility criteria for clinical trials report challenges in representing LN patients
- Celltrion implements Veeva Vault eTMF to improve visibility into clinical trial activities
- Longboat Clinical launches Patient CONNECT to ease patient recruitment process
UCB’s trial of bimekizumab in psoriasis patients meets goals
UCB has announced that the Phase III BE VIVID clinical trial of its bimekizumab met all primary and key secondary endpoints in moderate-to-severe chronic plaque psoriasis patients.
Worldwide selects ClinSpark eSource platform to automate trials
Worldwide Clinical Trials has implemented Foundry Health’s ClinSpark eSource Platform to automate Phase I first-in-human clinical trials for clinical development.
Boehringer begins enrolment in Phase II BALANCE-CF1 trial
Boehringer Ingelheim has enrolled the first patient in the Phase II BALANCE-CF study investigating an inhaled epithelial sodium channel (ENaC) inhibitor, BI 1265162, to treat cystic fibrosis.
Verona Pharma closes enrolment in Phase IIb COPD trial
UK-based biopharmaceutical firm Verona Pharma has completed patient enrolment in a Phase IIb clinical trial of nebulised ensifentrine (RPL554) to treat moderate-to-severe chronic obstructive pulmonary disease (COPD).
Lilly’s pegilodecakin fails in Phase III pancreatic cancer trial
Eli Lilly has reported that the Phase III SEQUOIA clinical trial of pegilodecakin failed to meet the primary endpoint of overall survival in patients with metastatic pancreatic cancer.
Novartis-Incyte’s Jakavi yields positive data in GvHD trial
Novartis and Incyte have reported positive results from the Phase III REACH2 clinical trial of Jakavi (ruxolitinib) conducted in steroid-refractory acute graft-versus-host disease (GvHD) patients.
Noxxon Pharma studies combination therapy for brain cancer
Noxxon Pharma has commenced a Phase I/II clinical trial to assess its CXCL12 inhibitor, NOX-A12, in combination with external-beam radiotherapy to treat newly diagnosed brain cancer.
PhaseBio doses first patient in ticagrelor antiplatelet activity trial
US-based clinical-stage biotechnology company PhaseBio Pharmaceuticals has dosed the first patient in a Phase IIb clinical trial of PB2452.
Trialbee collaborates with TriNetX for patient-centric trials
Patient recruitment firm Trialbee has partnered with health research network TriNetX for data-driven digital solutions to speed-up patient-centric clinical trials.